Polymorphic Variants of CYP2C9: Mechanisms Involved in Reduced Catalytic Activity

Lian Wei,1 Charles W. Locuson,2 and Timothy S. Tracy

Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota

Received March 20, 2007; accepted August 7, 2007

ABSTRACT

CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation. To assess the reasons for these reductions in catalytic activity of the two variants and potential substrate concentration-dependent differences in a biphasic kinetics substrate, cytochrome P450 P450 (P450) cycle coupling and uncoupling were monitored during coincubation of (S)-naproxen and CYP2C9 over a range of P450 reductase concentrations. Coupling was greatest in the CYP2C9.1 enzyme, followed by CYP2C9.2, and then CYP2C9.3. Uncoupling in CYP2C9.1 and CYP2C9.3 was primarily to H2O2. In contrast, CYP2C9.2 uncoupled to excess water preferentially. The conversion of enzyme to the high spin state was similar in CYP2C9.1 and CYP2C9.2, but lower in CYP2C9.3. It is noteworthy that neither altered substrate binding nor altered interaction with reductase seemed to be involved in reduced catalysis. These results suggest that in addition to coupling differences, differential uncoupling to shunt products and differences in spin state help explain the reduced catalytic activity in these enzymes.

The cytochrome P450 (P450) enzymes are responsible for the biotransformation of a wide range of exogenous and endogenous substrates (Wrighton and Stevens, 1992). P450-mediated metabolism occurs via a catalytic cycle (Scheme 1) that involves several steps: 1) substrate binding; 2) one-electron addition to the substrate-P450 complex by CPR; 3) oxygen binding to the ferrous P450; 4) transfer of a second electron by either CPR or cytochrome b5 and protonation of the resulting iron-peroxo anion intermediate; 5) cleavage of the O–O bond to generate H2O2; 6, 7) oxidation of the substrate; and 8) release of product with subsequent regeneration of ferric P450 (Schlichting et al., 2000; Ortiz de Montellano and De Voss, 2002; Groves, 2003). However, this cycle does not always result in the production of metabolic product. Three abortive reactions may occur during the catalytic cycle, resulting in the production of shunt products and returning of the P450 to its ferric state, including 1) auto-oxidation of the oxy-ferrous P450 to generate superoxide anion; 2) release of the hydroperoxo species to produce hydrogen peroxide (hydrogen peroxide may also be produced from dismutation of the superoxide anion produced in 1); and 3) four-electron reduction of dioxygen with the formation of one extra molecule of water (Gorsky et al., 1984; Loida and Sligar, 1993; Bernhardt, 1996). Together, these reactions are collectively referred to as the uncoupling of the P450 catalytic cycle.

CYP2C9 is one of the major human hepatic cytochrome P450 isoforms, and it is responsible for the metabolism of several commonly used drugs, such as (S)-warfarin (Rettie et al., 1992), phenytoin, tolbutamide (Veronese et al., 1991), and a number of nonsteroidal anti-inflammatory drugs (Zhao et al., 1992; Leemann et al., 1993; Rodrigues et al., 1996; Tracy et al., 1996). In addition, polymorphic variants of CYP2C9 have been identified as being expressed in several human populations. The most common (and studied) allelic variants of CYP2C9, apart from the wild-type CYP2C9.1, are CYP2C9.2 (R144C) and CYP2C9.3 (I359L), which are most commonly observed in the white population and exhibit reduced metabolism of most substrates both in vitro and in vivo (Furuya et al., 1995; Haining et al., 1996; Stubbs et al., 1996; Sullivan-Klose et al., 1996; Steward et al., 1997; Yamazaki et al., 1998; Takekoshi et al., 2000; Higashi et al., 2002). Naproxen [(S)-6-methoxy-α-methyl-2-napthalenecarboxylic acid], an nonsteroidal anti-inflammatory drug, has been widely used in the treatment of pain or inflammation, and it is marketed commercially as the (S)-enantiomer. The oxidative biotransformation of naproxen seems to result in the formation of a single demethylated metabolite, desmethyl-naproxen (Thompson and Collins, 1973). It is noteworthy that this naproxen demethylation is mediated primarily by
CYP2C9, and it exhibits biphasic atypical (non-Michaelis-Menten) kinetics, suggesting that two naproxen molecules may bind in the active site simultaneously with different kinetic properties (low \( K_m \)-low \( V_{max} \) and high \( K_m \)-high \( V_{max} \)) (Tracy et al., 1997; Korzekwa et al., 1998).

The effects of CYP2C9.1, CYP2C9.2, and CYP2C9.3 on the metabolism of (S)-naproxen and the resulting kinetic profiles have been reported previously (Tracy et al., 2002; Hummel et al., 2004). Biphasic kinetics have been observed with the wild-type enzyme. The CYP2C9.2 variant also exhibited biphasic kinetics but with a modest reduction in reaction velocity, whereas linear kinetics and a substantial reduction in reaction velocity were observed with the CYP2C9.3 variant over the concentration range studied. However, to date, no studies have been conducted to assess the effects of the CYP2C9 allelic variants on the P450 reaction cycle with respect to coupling and uncoupling of substrate metabolism and the role this plays in reduced reaction velocity. Furthermore, the coupling and uncoupling of a substrate such as (S)-naproxen that exhibits atypical kinetics due to the presumed simultaneous binding of two substrate molecules is unknown. To this end, a series of experiments were conducted with the simplest catalytically active P450 system (P450, CPR, and lipid) to assess the reaction stoichiometry of this process in CYP2C9.1, CYP2C9.2, and CYP2C9.3. The proportion of CPR to P450 was studied over a range of ratios to assess the effects of this redox partner in each of the enzymes. Furthermore, substrate-induced effects on the heme iron spin-state equilibrium were monitored to explain differences in P450 reaction cycle coupling and uncoupling.

### Materials and Methods

**Chemical and Reagents.** Acetonitrile, potassium phosphate, and sodium hydroxide were purchased from Thermo Fisher Scientific (Waltham, MA). NADPH, dilauroylphosphatidylcholine, (S)-naproxen, xylenol orange sodium salt, hydrogen peroxide solution (30%), ammonium iron(II) sulfate, d-sorbitol, sulfuric acid, \( \alpha \)-ketoglutarate, d-\((S)-(+)\)-three-isocitric acid monopotassium salt, isocitrate dehydrogenase, trichloroacetic acid, sodium dithionite, and aniline were obtained from Sigma-Aldrich (St. Louis, MO). 2,4-Dinitrophenylhydrazine was obtained from Spectrum Chemical (Gardena, CA). 2-Fluoro-4-biphenyl acetic acid was a gift from the former Pharmacia Co. (Kalamazoo, MI). Desmethylnaproxen was a gift from the former Syntex Laboratories (Palo Alto, CA). Recombinant human CPR was purchased from Invitrogen (Carlsbad, CA).

**Enzyme Expression and Purification.** The full-length human CYP2C9 and variants were expressed in Escherichia coli (DH5α-F′) and purified as described previously (Cheesman et al., 2003; Hummel et al., 2005). Constructs contained the full-length N-terminal membrane-binding helix, but residues 2 to 8 were mutated to a mitochondrial P450 sequence (ALLLAVF) to aid expression in E. coli (Barnes et al., 1991). A 6× histidine tag was added to the C terminus to facilitate purification. P450 concentration was determined using the method of Omura and Sato (1964) and an extinction coefficient of 91 mM\(^{-1}\) cm\(^{-1}\) for the reduced carbon monoxide-complexed enzyme.

**Enzyme Reconstitution and Incubation Conditions.** Enzyme reconstitution and incubation conditions were described previously (Tracy et al., 2002). Purified enzymes were reconstituted in dilauroylphosphatidylcholine vesicles (extruded through a 200-nm pore size membrane), with human P450 reductase (Invitrogen, Carlsbad CA) in various ratios. The quantity of enzyme used per incubation varied depending on the assay (5–20 pmol for metabolite and \( \text{H}_2\text{O}_2 \) assays and 30 pmol for NADPH assays). To determine the kinetics of the reaction, the CYP2C9 enzyme mixtures were incubated with nine concentrations
of (S)-naproxen (20–2100 μM) in the presence of 50 mM potassium phosphate buffer, pH 7.4, at 37°C in a final volume of 200 μl. After a 3-min preincubation, reactions were initiated by the addition of NADPH (1 mM). After 20 min, reactions were quenched by the addition of 200 μl of acetonitrile containing 180 ng of 2-fluoro-4-biphenyl acetic acid (internal standard) and then with 40 μl of 50% (v/v) concentrated H₃PO₄. The same procedures with minor modification were used in the experiments aimed at measuring metabolite and H₂O₂ in the same reaction. In these cases, 10 pmol of P450 was incubated with various ratios (0.25–16) of human CPR and (S)-naproxen at a concentration of either 150 or 1500 μM for 16 min and quenched by the addition of 20 μl of acetonitrile. Aliquots (50 μl) were then removed for measurement of hydrogen peroxide (see below), whereas to the remainder, 100 μl of acetonitrile containing 480 ng of 2-fluoro-4-biphenyl acetic acid (internal standard) and 27 μl of 7.4 M H₃PO₄ were added and processed as described above for measurement of metabolite. The samples were centrifuged at 10,000g for 4 min, and 50 μl of supernatant was directly injected onto the high-performance liquid chromatography system. Under these conditions, metabolite formation was linear with respect to time and P450 concentration. All experiments were performed at least in duplicate.

**Quantitation of Desmethylnaproxen Formation.** Measurement of desmethylnaproxen formation by high-performance liquid chromatography after incubation of (S)-naproxen was carried out exactly as described previously (Tracy et al., 1997).

**Kinetic Data Analysis.** The formation of desmethylnaproxen from (S)-naproxen was fit to a biphasic kinetic expression using nonlinear regression:

\[
v = \frac{(V_{max} \times [S]) \times (CL_{max} \times [S]^2)}{K_m + [S]} \quad (1)
\]

or a linear equation:

\[
v = CL_{max} \times [S] \quad (2)
\]

All data fitting was performed with SigmaPlot 8.0 (Systat Software, Inc., Point Richmond CA), and appropriateness of the fits was determined by examination and comparison of the residuals, residual sum of squares, coefficients of determination, and F values.

**Hydrogen Peroxide Assay.** Hydrogen peroxide produced during incubations of CYP2C9 with or without (S)-naproxen was monitored with the xylene orange dye method (Jiang et al., 1997). Fresh xylene orange reagent was prepared daily from stocks of 1 M D-sorbitol, 25 mM ammonium Fe(II) sulfate in 2.5 M H₂SO₄, and 10 mM xylene orange sodium salt. Working reagent was prepared by adding D-sorbitol (final concentration 0.1 M), xylene orange (final concentration 125 μM), and ammonium Fe(II) sulfate (10% of total volume) sequentially to distilled water. Enzyme reactions were carried out for 16 min. At the end of the incubation, 20 μl of acetonitrile was used to stop the reaction, and a 50-μl aliquot of the mixture was added to 450 μl of freshly prepared xylene orange reagent. Samples were allowed to stand for 45 min at room temperature, and then the absorbance was measured at 560 nm (Aminco DW2000 UV-Vis spectrophotometer with Olis upgrade; Olis Inc., Bogart, GA) after blanking the spectrophotometer with an identically prepared enzyme incubation, minus NADPH. The rate of hydrogen peroxide consumption at each CPR:P450 ratio was calculated as the difference between corresponding absorbances measured in the presence and absence of substrate, and compared with a standard curve generated with 1 to 50 μM hydrogen peroxide (assuming an extinction coefficient of 43.6 M⁻¹ cm⁻¹ at 240 nm).

**Assay of NADPH Consumption.** NADPH consumption during reaction of substrate with each of the CYP2C9 enzymes was measured spectrophotometrically based on the conversion of isocitrate to α-ketoglutarate by isocitrate dehydrogenase in the incubation mixtures and the subsequent reaction of the formed α-ketoglutarate with 2, 4-dinitrophenylhydrazine (Friedemann, 1957). Reaction conditions were optimized from previously described methods (Anthon and Barrett, 2003). The enzyme incubation reactions were allowed to proceed for 15 min at 37°C, and then they were quenched with trichloroacetic acid (20 μl of 70% solution) and centrifuged for 5 min at 10,000 rpm in a microcentrifuge. Fifty microliters of a 60 mg/100 ml solution of 2,4-dinitrophenylhydrazine was then added to 250 μl of the resulting supernatant, and the samples were placed in a 37°C water bath for 10 min. The samples were then removed, 100 μl of 5 M NaOH was added, and the absorbance at 515 nm was immediately measured in a DU 530 UV-Vis spectrophotometer (Beckman Coulter, Fullerton, CA). The spectrophotometer was blanked with a control enzyme incubation devoid of NADPH. Control incubations where substrate was absent were carried out at each CPR:P450 ratio studied and subtracted from the absorbance readings measured in the presence of substrate. Standard curves were prepared over the range of 0 to 50 nmol of α-ketoglutarate in 50 mM potassium phosphate buffer, and they were processed in the same manner as enzyme incubations.

**Estimation of Excess Water Formation.** Based on Scheme 1, it is assumed that part of the total consumed NADPH is used to form metabolite and H₂O₂, and the remainder is consumed to produce excess water. Because two molecules of NADPH are consumed for every one molecule of H₂O₂ produced, the relationship is equal to 2. Thus, the following equation modified from (Fang et al., 1997) was used to estimate the rate of excess water formation:

\[
\text{H}_2\text{O} = \frac{(\text{NADPH} - (\text{Metabolite} + \text{H}_2\text{O}_2))}{2} \quad (3)
\]

**Spectral Binding.** Absolute spectra were obtained to evaluate enzyme-substrate affinity as reported previously (Kumar et al., 2006), based on the alteration in heme iron spin state that occurs when active site water(s) is displaced through (S)-naproxen binding. In brief, 200 pmol of enzyme and 0.5 μg/pmol DLPC in 50 mM potassium phosphate buffer, pH 7.4, were placed into the sample cuvette. The reference cuvette only contained DLPC and potassium phosphate buffer. To determine the spectral changes occurring with increasing concentrations of (S)-naproxen (5–1000 μM), equal volumes of stock (S)-naproxen were added into both the sample and reference cuvettes, and a 3-min equilibrium interval was allowed between readings. Spectral binding experiments were conducted on the Aminco DW2000 spectrophotometer described above by scanning from 340 to 500 nm. This method helps prevent the large signal of naproxen from interfering with the spectrum of the enzyme. The temperature of the cell was held constant at 30°C with a Julabo F12 compact refrigerated circulator with an external Julabo ED temperature controller (Julabo USA, Inc., Allentown, PA). The difference in absorbance between high-spin (390-nm) and low-spin (418-nm) components was calculated and plotted against (S)-naproxen concentration. The data were fit by nonlinear regression SigmaPlot 8.0 (Systat Software, Inc.) to estimate the spectral binding constant (Kₛ) from the titration binding curve using the following equation:

\[
\Delta A = \frac{B_{max1} \times [S]}{K_{a1} + [S]} + \frac{B_{max2} \times [S]}{K_{a2} + [S]} \quad (4)
\]

The equilibrium dissociation constant (Kₛ) of the CPR-CYP2C9 complex was determined by measuring the spectral change occurring when CPR is added to a solution containing 200 pmol of CYP2C9 enzyme and 0.5 μg/pmol DLPC with 50 mM potassium phosphate buffer, pH 7.4, and 20% glycerol, analogous to the method used to determine the cytochrome b₅ dissociation constant with rabbit CYP2B4 (Tamburini et al., 1985). Experiments were conducted with the spectrophotometer used for monitoring naproxen binding. The reference cuvette contained DLPC, phosphate buffer, and glycerol. CPR was titrated into both sample and reference cuvettes over the range of 0.001 to 9.0 μg/mL, and samples scanned from 340 to 500 nm to obtain the absorbance difference of the low- (418-nm) and high-spin (390-nm) Soret bands. Experiments were carried out at 30°C, and samples were equilibrated for 20 min after each addition of CPR. Because the Kₛ value of CPR to CYP2C9 was estimated to be much lower than the concentration of CYP2C9, and
because multiple binding events were evident, the resulting absorbance data were fit using DynaFit (Biokin, Inc., Pullman WA). The largest change in absorbance was achieved before an equimolar amount of CPR had been added to the CYP2C9 enzymes. This possibly indicates that only some of the P450 sample is available to CPR or that multiple complexes containing oligomers of P450 and/or CPR form and have different extinction coefficients. Because a second binding phase at higher CPR concentrations was observed, but the exact P450 oligomer-CPR complexes being formed are not known, the data were fit to two simple equilibria where [P450] was constant: P450 + CPR ⇌ P450 × CPR and P450 × CPR + CPR ⇌ CPR × P450 × CPR. These expressions are dependent on [CPR], and they do not consider different P450 oligomers or conformations, but functionally they are similar to the more probable scenario P450 + P450 × CPR + 2CPR ⇌ P450 × CPR + P450 × P450 × CPR, where oligomeric state or changes in the oligomeric state are associated with distinct absorbivities. It is not clear what species exist either in vitro or in vivo, but these events can be assumed to be more complex than 1:1 binding.

**Spin-State Analysis.** Substrate-induced spin state changes with the three CYP2C9 enzymes were measured as described above for spectral binding measurements. Spectral titrations with (S)-naproxen (150 and 1500 µM final concentrations) were performed by adding equal volumes of stock (S)-naproxen to both sample and reference cuvettes followed by spectral scanning between 320 and 500 nm. Before scanning, the sample and reference cuvettes were allowed to equilibrate for 3 min with enzyme and substrate. Absolute spectra were then obtained to estimate the percentage of conversion of CYP2C9 from low spin to high spin using the relative low-spin peak area (Roberts et al., 2005). Deconvolution of spectra was carried out with the multiple Gaussian curve fitting available in Origin Pro, version 7.5 (OriginLab Corp., Northampton, MA). The model was developed to include three components: a low-spin component (~416–420 nm), a high-spin component (~390–405 nm), and δ-bands (~360 nm). Aniline (25 mM) was used to convert the relatively small amount of high-spin enzyme (in the absence of substrate) to the low-spin state followed by peak deconvolution. The resulting low-spin peak area was then used as the low-spin reference. The amount of low-spin heme iron is correlated to the low-spin peak areas deconvoluted from samples of different P450 concentrations ($R^2 = 0.99$).

**Results**

**Desmethylnaproxen Formation.** Kinetic profiles for the CYP2C9-mediated formation of desmethylnaproxen from (S)-naproxen are presented in Fig. 1A. Metabolism by CYP2C9.1 and CYP2C9.2 was best fit with a biphasic kinetics equation (eq. 1), whereas the formation of metabolite by CYP2C9.3 was best fit by a linear equation (eq. 2). At low substrate concentration (<200 µM), CYP2C9.1 and CYP2C9.2 produced similar metabolite formation rates, although these values diverged at substrate concentrations beyond 200 µM. Production of desmethylnaproxen from (S)-naproxen (1500 µM) was evaluated over a range of CPR:P450 ratios, 0.25 to 16 (Fig. 1B). Metabolism of (S)-naproxen by CYP2C9.1 and its variants was also assessed at low (S)-naproxen concentration (150 µM) (Table 1) at a fixed CPR:P450 ratio of 2. The relative ranking of metabolite formation rates at 150 µM (S)-naproxen was the same as with the high concentration of (S)-naproxen (1500 µM). In all cases, metabolism increased up to a CPR:P450 ratio of either 2 or 4, and then it began to decrease with all three enzymes. Differences in metabolite formation were evident among the three enzymes, with CYP2C9.1 exhibiting the highest metabolite formation rate at each CPR:P450 ratio (CYP2C9.1 > CYP2C9.2 > CYP2C9.3) except at the very highest CPR:P450 ratios where the metabolite formation rates for CYP2C9.1 and CYP2C9.2 were essentially equivalent. In addition, CYP2C9.1 exhibited the greatest percentage of change in metabolite formation of the three enzymes (CYP2C9.1 > CYP2C9.2 > CYP2C9.3) at increasing reductase concentrations. Dialysis of glycerol from CPR did not alter these effects of CPR concentration.

**Hydrogen Peroxide Formation.** The degree to which P450 reaction cycle uncoupling yields H$_2$O$_2$ was evaluated at various CPR:P450 ratios at an (S)-naproxen concentration of 1500 µM (Fig. 2A). H$_2$O$_2$ formation rates increased up to a CPR:P450 ratio of 2 for each of the enzymes, then they decreased in all three cases at higher ratios of CPR:P450. CYP2C9.3 produced more H$_2$O$_2$ than CYP2C9.2 but less than CYP2C9.1. In the CYP2C9.2 enzyme, increasing reductase ratios had the least effect on production of H$_2$O$_2$. Using a low concentration of (S)-naproxen (150 µM) and a CPR:P450 ratio of 2, the relative rankings of the enzymes with respect to H$_2$O$_2$ formation (CYP2C9.1 > CYP2C9.2 > CYP2C9.3) differed from that observed at higher (S)-naproxen concentrations (Fig. 2A, Table 1).

**NADPH Consumption.** To ascertain whether the amino acid changes present in the CYP2C9.2 and CYP2C9.3 enzymes affect electron transfer from CPR to P450, NADPH consumption was monitored with (S)-naproxen (1500 µM) and a range of CPR concentrations (Fig. 2B). The NADPH consumption rate increased up to a CPR:P450 ratio of 1, and then it decreased at higher CPR:P450 ratios in all three

---

**Fig. 1.** (S)-Naproxen demethylation by CYP2C9. (A) (S)-Naproxen demethylation by CYP2C9.1, CYP2C9.2 and CYP2C9.3. Lines indicate the nonlinear regression fit of the data to either eq.1 (CYP2C9.1 and CYP2C9.2) or eq.2 (CYP2C9.3). (B) Desmethylnaproxen formation by CYP2C9.1, CYP2C9.2 and CYP2C9.3 at various ratios of CPR:P450 (0.25, 0.5, 1, 2, 4, 8, 12, and 16). Each data point is the mean of triplicate determinations.
enzymes. Furthermore, CYP2C9.2 exhibited a rate of NADPH consumption similar to CYP2C9.1, although NADPH consumption was lowest with CYP2C9.3. Rankings of NADPH consumption across the enzymes at low (S)-naproxen concentration (150 μM) was identical to that observed at high naproxen concentrations (CYP2C9.2 > CYP2C9.1 > CYP2C9.3).

**Estimates of Excess Water Formation.** Excess water formation was estimated from eq. 3. Estimated excess water formation rates were higher with CYP2C9.2 compared with either of the other enzymes at all CPR:P450 ratios studied (Fig. 2C). Comparatively little excess water was formed by CYP2C9.3, and increasing reductase concentrations did not increase excess water formation substantially, as occurred with CYP2C9.1 and CYP2C9.2. Estimation of excess water was also attempted by measuring oxygen consumption with an oxygen electrode, but because of analytical sensitivity limitations, we were unable to estimate excess water formation at CPR:P450 ratios of 2 and higher with CYP2C9.1 and CYP2C9.3 at either (S)-naproxen concentration. For CYP2C9.2, increasing the substrate concentration resulted in increased excess water formation. However, with CYP2C9.3 the opposite occurred in that an increase in substrate concentration resulted in a decrease in excess water formation.

**Effects of Different CPR:P450 Ratios on Coupling and Uncoupling.** The ratio of metabolite formation:NADPH consumption, a measure of overall efficiency of coupling reducing equivalents to metabolite formation in the P450 reaction cycle, increased as the CPR:P450 ratio was raised (Fig. 3A). At each fixed CPR:P450 ratio, CYP2C9.1 exhibited the highest metabolite/NADPH ratio (CYP2C9.1 > CYP2C9.2 > CYP2C9.3), being the most coupled of the three CYP2C9 enzymes studied.

The H\textsubscript{2}O\textsubscript{2} formation:NADPH consumption ratio can be used as a direct measure of uncoupling to the product H\textsubscript{2}O\textsubscript{2}, which can be formed either at the first or second branch points (with the assumption that superoxide formed at the first branch point dismutates to hydrogen peroxide under experimental conditions). Uncoupling to H\textsubscript{2}O\textsubscript{2} increased as the CPR:P450 ratio was raised (Fig. 3B). The H\textsubscript{2}O\textsubscript{2}:NADPH ratio was greatest for CYP2C9.3 (CYP2C9.3 > CYP2C9.1 > CYP2C9.2). The CYP2C9 reaction cycle is least likely to uncouple to H\textsubscript{2}O\textsubscript{2} with CYP2C9.2.

From Table 1, it is apparent that at the low (S)-naproxen concentration (150 μM), coupling (metabolite/NADPH ratio) was substantially lower in all three enzymes compared with that observed at the high concentration of substrate. At the high (S)-naproxen concentration (1500 μM), CYP2C9.1 coupling was approximately 4-fold, CYP2C9.2 was 2-fold, and CYP2C9.3 was 13-fold higher than observed at the low substrate concentration. For CYP2C9.1 and CYP2C9.2, uncoupling (H\textsubscript{2}O\textsubscript{2}:NADPH ratio) was decreased at the higher substrate concentration compared with uncoupling to H\textsubscript{2}O\textsubscript{2} at the low (150 μM) substrate concentration.

**Spectral Binding.** To assess whether differences in (S)-naproxen binding exist among the three CYP2C9 enzymes, titration studies of P450 heme spectral changes against (S)-naproxen concentrations (Fig. 4, inset) were conducted. Plotting the difference in absorbance between 418 and 390 nm versus increasing (S)-naproxen concentrations yielded biphasic curves (Fig. 4), suggesting multiple binding events of (S)-naproxen in all three CYP2C9 enzymes. The $K_a$ of (S)-naproxen with the saturable, high-affinity site of CYP2C9.1 ($K_a = 26.9 \pm 1.3$ μM) is close to that of CYP2C9.3 ($K_a = 30.4 \pm 4.9$ μM). It is noteworthy that the affinity of (S)-naproxen for CYP2C9.2 ($K_a = 8.6 \pm 0.7$ μM) is somewhat lower.

**TABLE 1**

Comparison of CYP2C9 reaction cycle, stoichiometry, coupling, and uncoupling at both low (150 μM) and high (1500 μM) (S)-naproxen concentrations

<table>
<thead>
<tr>
<th>[S]-naproxen</th>
<th>Metabolite Formation</th>
<th>H\textsubscript{2}O\textsubscript{2} Formation</th>
<th>NADPH Consumption</th>
<th>Metabolite/NADPH</th>
<th>H\textsubscript{2}O\textsubscript{2}/NADPH</th>
<th>Excess H\textsubscript{2}O</th>
</tr>
</thead>
<tbody>
<tr>
<td>μM</td>
<td>pmol/min/pmol of P450</td>
<td>pmol/min/pmol of P450</td>
<td></td>
<td></td>
<td></td>
<td>pmol/min/pmol of P450</td>
</tr>
<tr>
<td>CYP2C9.1</td>
<td>150</td>
<td>1.3 ± 0.1</td>
<td>13.6 ± 0.6</td>
<td>13.7 ± 3.0</td>
<td>0.09</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td>1500</td>
<td>10.3 ± 1.0</td>
<td>21.2 ± 2.0</td>
<td>24.8 ± 2.0</td>
<td>0.42</td>
<td>0.85</td>
</tr>
<tr>
<td>CYP2C9.2</td>
<td>150</td>
<td>5.4 ± 0.6</td>
<td>11.4 ± 0.6</td>
<td>30.3 ± 3.7</td>
<td>0.18</td>
<td>0.38</td>
</tr>
<tr>
<td></td>
<td>1500</td>
<td>0.6 ± 0.01</td>
<td>4.4 ± 0.2</td>
<td>8.7 ± 3.2</td>
<td>0.01</td>
<td>0.51</td>
</tr>
<tr>
<td>CYP2C9.3</td>
<td>150</td>
<td>2.0 ± 0.4</td>
<td>17.5 ± 2.0</td>
<td>15.2 ± 4.5</td>
<td>0.13</td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td>1500</td>
<td>0.06 ± 0.01</td>
<td>4.4 ± 0.2</td>
<td>8.7 ± 3.2</td>
<td>0.01</td>
<td>0.51</td>
</tr>
</tbody>
</table>

* Not accurately estimable because of analytical sensitivity limitations.

![Fig. 2](image-url) Effect of CPR:P450 ratio on CYP2C9 stoichiometry in the presence of 1500 μM (S)-naproxen. A, H\textsubscript{2}O\textsubscript{2} formation; data points represent the mean (n = 3). B, NADPH consumption; data points represent the mean (n = 3). C, estimates of excess H\textsubscript{2}O formation rates.
greater than with the other two enzymes. $K_s$ values for the unsaturable, low-affinity (S)-naproxen binding site could not be determined accurately because the estimated $K_s$ values (>10 mM) are greater than (S)-naproxen solubility in phosphate buffer. Characterization of CPR binding with the three CYP2C9 enzymes was also studied by assessing the ability of CPR to affect the heme iron spin state. $K_d$ values of the first binding event of CPR with the three CYP2C9 enzymes (Fig. 5) were also determined ($K_d, 2C9.1 = 2.3 \pm 1.0 \text{ nM}$; $K_d, 2C9.2 = 1.1 \pm 0.4 \text{ nM}$; and $K_d, 2C9.3 = 1.7 \pm 0.7 \text{nM}$). These values are virtually indistinguishable suggesting that CPR interacts with all three CYP2C9 enzymes with equal affinity.

**Spin-State Changes in CYP2C9 Enzymes upon (S)-Naproxen Binding.** The percentage of each of the CYP2C9 enzymes existing in the low and high spin states was determined at both low (150 μM) and high (1500 μM) (S)-naproxen concentrations. The conversion of CYP2C9.1 low spin species to the high spin form is essentially the same as measured from CYP2C9.2, regardless of (S)-naproxen concentration (Table 2). Substrate binding introduced less spin conversion in CYP2C9.3. Conversion of CYP2C9.3 to the high-spin species was roughly half that observed with other enzymes when incubated with (S)-naproxen, although increasing (S)-naproxen concentration did increase the fraction of high-spin species.

**Discussion**

Genetic variation in drug-metabolizing enzymes can have profound effects on the catalytic activity of P450s, as has been observed with CYP2C9.2 and CYP2C9.3 (Yamazaki et al., 1998; Tracy et al., 2002; Iida et al., 2004). However, little is known regarding the mechanism(s) responsible for these changes in activity. The CYP2C9*2 mutation (R144C) alters
an amino acid on the outer surface of the enzyme, whereas the CYP2C9.3 enzyme results from a conservative, single amino acid change (I359L) on the interior of the enzyme. However, crystallography studies (Wester et al., 2004) suggest that the I359L substitution is not likely to be directly involved in substrate binding, implying that a mechanism other than alterations in substrate binding may be responsible for the decrease in catalytic activity. To this end, a series of investigations were undertaken to better understand the mechanism(s) responsible for altered catalytic activity with CYP2C9.2 and CYP2C9.3.

CYP2C9 polymorphisms altered coupling efficiency (metabolite:NADPH ratio) in the presence of the substrate (S)-naproxen. Both variants, CYP2C9.2 and CYP2C9.3, exhibited decreased coupling efficiency. Because (S)-naproxen demethylation exhibits a biphasic kinetic profile, concentrations of 150 and 1500 μM thought to approach the V_max of each of the respective kinetic phases (low K_m-low V_max and high K_m-high V_max, respectively) were used to evaluate the effect of substrate concentration on coupling efficiency. When comparing results at the lower (150 μM) (S)-naproxen concentration to the higher (1500 μM) concentration, CYP2C9.3 exhibited the greatest increase in coupling (~13-fold) when substrate concentration was increased.

It has been reported that substrate binding triggers the first electron transfer to the P450 heme iron, serving to initiate the P450 catalytic cycle (Sligar and Gunsalus, 1976). In evaluating the NADPH consumption data, it seems that CYP2C9.2 triggers slightly more P450 catalytic cycles per unit time than the other two variants, but it is less productive with respect to desmethylnaproxen formation. Crespi and Miller (1997) have proposed that the R144C change in CYP2C9.2 reduces substrate metabolism through effects on the interaction of P450 with CPR, because this amino acid is located outside the active site, near the outer surface of the protein. If this were the case, one would not expect the CYP2C9.2 protein to exhibit comparable NADPH consumption rates, and likewise, the metabolite formation rate should be diminished at all substrate concentrations compared with wild-type enzyme (see above) and not just at higher substrate concentrations. The similar K_d values for the CYP2C9-CPR complex observed with CYP2C9.1 and CYP2C9.2 further supports the notion that altered reductase interactions are not responsible for the diminished substrate turnover observed with CYP2C9.2. It is of note that the binding of CPR to P450 seemed to be biphasic. This finding combined with the estimated K_d value for CPR with either enzyme being lower than the enzyme concentration present in the experimental matrix suggests that binding of CPR to both individual P450 molecules and P450 oligomer complexes may occur, resulting in the biphasic binding results noted (Hazai et al., 2005).

Increasing CPR concentrations improved coupling efficiency to different extents in each of the three enzymes. The CPR concentration that results in optimal rates for metabolite formation and NADPH consumption will be dependent on the conditions of reconstitution, but CPR was not saturating at P450:CPR ratios (e.g., 1:2) typically used for in vitro studies. Furthermore, it is proposed that the decrease in metabolite formation and NADPH consumption rates at higher CPR:P450 ratios may be due to differences in the rate of P450 reduction. Other investigators have suggested that multiple reduction states of CPR could be involved in P450 reduction (Oprian et al., 1979; Oprian and Coon, 1982). This is further supported by work with CYP2B4 by Reed and Hollenberg (2003) who demonstrated that with binding of certain substrates, the conformation of P450 does not allow CPR to bind in an orientation that allows for optimal reduction to occur (even in the presence of excess reductase), thus giving rise to the multiphasic presteady-state reduction of P450. Given that metabolite formation rate decreased at higher CPR:P450 ratios, it is tempting to speculate as to an “inhibitory”
The effect of CPR at higher concentrations. However, it should be noted that although metabolite formation rate decreased with increasing CPR (Fig. 1B), the efficiency of the reaction cycle actually continued to increase with increasing CPR concentrations (Fig. 3, A and B) due to the even more pronounced decrease in NADPH consumption rate. Thus, the effects of higher CPR concentrations are complex and multifaceted. To ensure that this inhibition of metabolite formation at higher CPR concentrations was not due to components in the CPR enzyme buffer (after purification), glycerol and glutathione were dialyzed away, and the rates were studied again. No differences were noted, suggesting that the observed effects are due to some undefined effects of CPR and not to components of the preparation (data not shown).

The $\text{H}_2\text{O}_2$ shunt is considered to be one of the abortive reactions in the P450 catalytic cycle. In the presence of 1500 $\mu$M (S)-naproxen, CYP2C9.3 was the most uncoupled to $\text{H}_2\text{O}_2$, whereas CYP2C9.2 was the least uncoupled (Fig. 3B). In contrast, at lower substrate concentrations (150 $\mu$M) uncoupling to $\text{H}_2\text{O}_2$ was highest for CYP2C9.1. Conversely, when one examines excess $\text{H}_2\text{O}$ formation (another uncoupling product), CYP2C9.2 exhibited both the highest amount of excess $\text{H}_2\text{O}$ formation, irrespective of substrate concentration and the greatest increase in excess $\text{H}_2\text{O}$ formation as the substrate concentration was increased. These results suggest that the amino acid change in CYP2C9.2 in some way results in the iron-oxene intermediate (Scheme 1) being more susceptible to breakdown to $\text{H}_2\text{O}$ than is the case with the other enzymes and that breakdown to this product is more likely than to other shunt products (i.e., superoxide and $\text{H}_2\text{O}_2$). That metabolite formation rates are similar for CYP2C9.1 and CYP2C9.2 at lower (<200 $\mu$M) (S)-naproxen concentrations, but they diverge at higher substrate concentrations, suggesting that binding of a second substrate molecule may play a role in this increased shunting. The decreased excess $\text{H}_2\text{O}$ formation with CYP2C9.3 in the presence of high substrate concentration suggests the P450 reaction cycle falls apart in the steps between $\text{H}_2\text{O}_2$ and excess $\text{H}_2\text{O}$ production. This increase in $\text{H}_2\text{O}_2$ production by CYP2C9.3 at higher substrate concentrations is also related to the increased cycle triggering as suggested by the corresponding increase in NADPH consumption.

Some earlier studies suggested that the heme iron spin state may survive as a surrogate marker (Sligar et al., 1979; Tamburini et al., 1984; Backes et al., 1985). Although not applicable for every P450 isoform (Eyer and Backes, 1992) as a result of differences in reduction potentials (Ost et al., 2003), CYP2C9 is always much faster in the presence of substrate even though the substrate oxidation rate may be slow (Guengerich and Johnson, 1997). The current results suggest that at low (S)-naproxen concentrations, fractional conversion to the high spin state is consistent with the kinetic data. At low (S)-naproxen concentrations, both CYP2C9.1 and CYP2C9.2 exhibit similar percentages of high-spin enzyme as well as metabolite formation rates, whereas both percentage of high-spin enzyme and metabolite formation are substantially lower for CYP2C9.3 (~6.5% high spin). With higher (S)-naproxen concentrations (1500 $\mu$M), despite similar percentages of high-spin enzyme, lower metabolite formation rate observed with the CYP2C9.2 enzyme. Yet, this difference was accounted for with the substantially greater formation of shunt products because the defect in the catalytic cycle with CYP2C9.2 is somewhere after the initial triggering. The low fraction of high-spin enzyme observed with CYP2C9.3 is notable. The ~2-fold increase in percentage of high-spin enzyme with increasing (S)-naproxen concentrations, although still remaining low (~11.8% high spin at 1500 $\mu$M (S)-naproxen), is associated with a 35-fold increase in metabolite formation and a 5-fold increase in $\text{H}_2\text{O}_2$ formation, suggesting differential effects of increasing substrate on coupling and uncoupling with CYP2C9.3. Sligar and associates have recently described similar findings (Denisov et al., 2007). As more than 1 mole of ligand binds to CYP3A4, higher substrate concentrations increased high-spin character along with metabolite formation such that the population of low-affinity binding sites had a substantial effect on the positioning of other bound substrates poised for oxidation.

It is noteworthy that the high-affinity site $K_s$ of (S)-naproxen with CYP2C9.1 and CYP2C9.3 was similar for these two enzymes (Fig. 4). This suggests that factors other than substrate binding and electron transfer (vide supra), such as alterations in the P450 catalytic cycle after cycle initiation, are responsible for the difference in coupling to product in CYP2C9.3 compared with the wild-type enzyme. Naganos and Poulos (2005) have proposed that a threonine (Thr252 in P450cam) widely conserved in P450s is required to stabilize the hydroperoxy intermediate (Scheme 1), favoring addition of the second proton over peroxide release, in addition to it delivering catalytic waters for dioxygen activation. In the present case, lack of change in substrate affinity and the finding that percentage of high-spin enzyme is substantially lower regardless of substrate concentration in CYP2C9.3 compared with CYP2C9.1 is consistent with alterations in the water network.

In summary, the CYP2C9 variants CYP2C9.1, CYP2C9.2, and CYP2C9.3 exhibit different degrees of coupling and uncoupling at differing concentrations of the redox partner CPR and substrate (S)-naproxen. Results suggest that alterations in the P450 catalytic cycle are responsible for CYP2C9.2 diminished metabolite formation rate, not alterations in CPR binding or electron transfer, as suggested previously. Destabilization of the iron-oxene complex seems to be responsible for the altered substrate turnover noted with CYP2C9.2. In the CYP2C9.3 variant, the percentage of high-spin enzyme present after substrate binding is very low compared with CYP2C9.1, despite similar substrate binding affinities, suggesting a disruption of the water network in the CYP2C9.3 variant. In addition, with CYP2C9.3, the P450 cycle seems to fail apart before formation of the iron-oxene complex. Despite only a 2-fold increase in high-spin enzyme when using higher substrate concentrations, desmethylnaproxen formation and

### TABLE 2

Comparison of spin-state fraction at different (S)-naproxen concentrations

<table>
<thead>
<tr>
<th>[S]-Naproxen</th>
<th>Low-Spin Content</th>
<th>Estimated High-Spin Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C9.1</td>
<td>150</td>
<td>84.4%</td>
</tr>
<tr>
<td></td>
<td>1500</td>
<td>77.3%</td>
</tr>
<tr>
<td>CYP2C9.2</td>
<td>150</td>
<td>79.8%</td>
</tr>
<tr>
<td></td>
<td>1500</td>
<td>75.0%</td>
</tr>
<tr>
<td>CYP2C9.3</td>
<td>150</td>
<td>93.5%</td>
</tr>
<tr>
<td></td>
<td>1500</td>
<td>88.2%</td>
</tr>
</tbody>
</table>

For low-spin content, data represent mean of duplicate determinations. Estimated high-spin content is 100% minus the low-spin content.
H$_2$O$_2$ formation increase disproportionately, suggesting that binding of the second naproxen molecule improves positioning of the first-bound naproxen, thereby leading to more efficient oxidation in the CYP2C9.3 enzyme. Thus, in the CYP2C9.2 and 2C9.3 variants, amino acid substitutions arguably not involved directly in substate binding destabilize or reduce formation of the iron-oxene complex, thereby resulting in reduced catalytic activity.

References


Address correspondence to: Dr. Timothy S. Tracy, Department of Experimental and Clinical Pharmacology, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455. E-mail: tracy017@umn.edu